Picture of BioNTech SE logo

BNTX BioNTech SE Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapSuper Stock

Annual cashflow statement for BioNTech SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

2017
December 31st
C2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS20-F20-F20-F20-F
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-85.9-47.7-179-14615,046
Depreciation
Non-Cash Items29.47.9431.1188-32.6
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-6.6-41.1-84.1-94.9-14,199
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities-52.6-58.9-199-13.5890
Capital Expenditures-57.7-67.2-71.1-85.4-154
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items5.190.705-6.04-59.4-412
Acquisition of Business
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-52.5-66.5-77.1-145-566
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities-1.6436538389594.2
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-132239108691483

Or unlock with your email

Or unlock with your email